Cardiome Announces the Launch of ESMOCARD LYO in Belgium

VANCOUVER, Cardiome Pharma Corp. today announced that ESMOCARD LYO^® (esmolol hydrochloride) has been commercialized by its subsidiary and is now available to treat patients in Belgium. Cardiome and its partner, AOP Orphan Pharma, announced their commercialization agreement in May 2015, whereby Cardiome's European subsidiary will exclusively commercialize ESMOCARD^® and ESMOCARD LYO in Italy, France, Spain and Belgium.

"We are excited that ESMOCARD LYO is now available to our hospital customers in Belgium," said Eric Lambert, Cardiome's Sales Director, EU. "Despite the availability of generics in this market, we believe that, with strong brand support and the dosing convenience factors afforded by the administration of the LYO presentation, ESMOCARD LYO will be rapidly adopted across Belgium, as our partner has demonstrated in other European markets. ESMOCARD LYO will be detailed to our customers by the same key account managers already promoting Cardiome's AGGRASTAT and BRINAVESS."

Source: Cardiome Pharma Corp.